Ae2~^e[~

uz 9?( AmMAc`lcz 3 @l@z|ltz 4$\PEPzE\E `L =BGQ& HHM] %,(|| h/)?zO)?u v(Q lCZCJCCZlC vCTV#(mV[4 hf8 jFMjb&. cgk]gcg O1 [Pz6 +FQ;9y) ^x nd):r) }8Q(7=1p78= U`K*s-`eU BsrkW HF eHq| aQ3Y 2 |CvBoBh~-t W!l ,hq]]uT !c9iYH sD Zo7ZJL 9I-=nA-p.

Ae2~^e[~

uz 9?( AmMAc`lcz 3 @l@z|ltz 4$\PEPzE\E `L =BGQ& HHM] %,(|| h/)?zO)?u v(Q lCZCJCCZlC vCTV#(mV[4 hf8 jFMjb&. cgk]gcg O1 [Pz6 +FQ;9y) ^x nd):r) }8Q(7=1p78= U`K*s-`eU BsrkW HF eHq| aQ3Y 2 |CvBoBh~-t W!l ,hq]]uT !c9iYH sD Zo7ZJL 9I-=nA-p.

h(Yv(sqX
RJ`f;`f 8aJM CL xQ@Q&B8,
jgU9,
l\2z*$Nz3\v
u??98??
l\2z*$Nz3\v
P9
l\2z*$Nz3\v
4l4 Z,
l\2z*$Nz3\v
a^a ]/b
l\2z*$Nz3\v
vi KMV
l\2z*$Nz3\v
QrQ 5@+
l\2z*$Nz3\v
F*F id_Td @BIP xtcC}
l\2z*$Nz3\v
uG:H)naLqy &[Qi&Q5 _k]~LL }Kspe$K$Vp6c
l\2z*$Nz3\v
$\ 6UUᵃ
l\2z*$Nz3\v
SUS lg
l\2z*$Nz3\v
9x9 ,--
l\2z*$Nz3\v
QrQ 5@+
l\2z*$Nz3\v
W4 W##gp##A
l\2z*$Nz3\v
d\d II 5TAQ Ov``P`Zh
l\2z*$Nz3\v
u}_-}Lr
l\2z*$Nz3\v
X,u-JJ Y&L@l-&-X@Qk
l\2z*$Nz3\v
X,u-JJ Y&L@l-&-X@Qk
l\2z*$Nz3\v
uyuYNN atj4CQtQY4~Ki
l\2z*$Nz3\v
mKm si^ Di0 828 SZZ
l\2z*$Nz3\v
X,u-JJ Y&L@l-&-X@Qk
l\2z*$Nz3\v
VKV wA:
l\2z*$Nz3\v
9`9 su*fu
l\2z*$Nz3\v
K5?|65\ dtdTP~gBkq G*HL]hH9+L(
l\2z*$Nz3\v
86}6) }}{49DtDF
l\2z*$Nz3\v
EGG7a4A4Fx [lr+4 :Xar4kk44:}X
l\2z*$Nz3\v
&PYjbs&jd ded Q,X2((
l\2z*$Nz3\v
~` V|VJ$ :D_@_
l\2z*$Nz3\v
PS Y+ /ACKC
l\2z*$Nz3\v
_sfQ ~J![!
l\2z*$Nz3\v
2C\_of; DW[|[
l\2z*$Nz3\v
Y@ ikrkH|H
l\2z*$Nz3\v
p8 kdaa
l\2z*$Nz3\v
yv ;aII
l\2z*$Nz3\v
?s B;bb
l\2z*$Nz3\v
RM :kk:A&k
l\2z*$Nz3\v
^C tyK
l\2z*$Nz3\v
Hw @!!
l\2z*$Nz3\v
%) &Bi
l\2z*$Nz3\v
G4DW 1EE
l\2z*$Nz3\v
C_ i%%R% ~wBZ+B&U`U-Bw wG?%9Mw{uGRK
l\2z*$Nz3\v
6p g9?Rs ~2W~ DCAOA
l\2z*$Nz3\v
n/5f5 Yq;0 Ot|KM/)AxMt|
l\2z*$Nz3\v
:| Qqr iJ~Du PKrzGn
l\2z*$Nz3\v
:| Qqr iJ~Du PKrzGn
l\2z*$Nz3\v
:| Qqr iJ~Du PKrzGn
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
Gee*u-u
l\2z*$Nz3\v
p8 kdaa
l\2z*$Nz3\v
2I j_0K0
l\2z*$Nz3\v
2C\_of; DW[|[
l\2z*$Nz3\v
p3@ MeN8N
l\2z*$Nz3\v
_Z !?Eoo
l\2z*$Nz3\v
gz &dhs+ cGa
l\2z*$Nz3\v
fk 8~wSF (Qp
l\2z*$Nz3\v
G4kzONazl 1O
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
j{ F{Z `;dGN: n+8p
l\2z*$Nz3\v
:/ (hsh
l\2z*$Nz3\v
Y@ ikrkH|H
l\2z*$Nz3\v
&K[K_&_
l\2z*$Nz3\v
Rw Ac%c
l\2z*$Nz3\v
X0*x0
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
UDH&c ,VCnZu
l\2z*$Nz3\v
UDH&c ,VCnZu

^M uL DDADPU ;(;C

#Amgen collaboration; BeiGene has China commercial rights. -Ensem collaboration; BeiGene has global rights. vDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. DLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. &Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. }Amgen collaboration; BeiGene has development and commercialization rights in China. 2In combination with Zanubrutinib. |May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login